Evaluation of V.A.C. VERAFLO CLEANSE CHOICE™ Dressing Using Normal Saline to Promote Increased Healthy Wound Bed Tissue

Not Applicable

Terminated

• Conditions: Wound Heal; Wound; Granulation Tissue; Wounds and Injuries; Negative-pressure Wound Therapy
• Interventions: Device: V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline

• Registration Number: NCT04026334
• Lead Sponsor: 3M

Brief Summary

The study goal is to evaluate the ability of the V.A.C. ULTA™ Negative Pressure Wound Therapy System and V.A.C. VERAFLO CLEANSE CHOICE ™ (VFCC) dressing system with saline as an irrigant in increasing viable tissue in full thickness wounds (such as chronic, acute, traumatic, sub-acute, and dehisced wounds and/or ulcers) with difficult to manage bioburden and slough.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-07-18
• Study First Submitted QC: 2019-07-18
• Study First Posted: 2019-07-19
• Study Start: 2019-07-25
• Primary Completion: 2020-08-28
• Study Completion: 2020-08-28
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-29
• Last Update Posted: 2022-08-01

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

1. is anticipated to be hospitalized for the duration of treatment.
2. is ≥22 years of age or their legally authorized representative is able to provide informed consent.
3. has a full thickness wound (such as chronic, acute, traumatic, sub-acute, and dehisced wounds and/or ulcers) measuring ≥4cm in length and ≥4cm in width (before removal of eschar at the bedside) excluding undermining/tunneling.
4. has, in the opinion of the investigator, no more than 2/3 of the visible wound bed surface area considered to be clean, healthy, and viable. If eschar is present at baseline, it must be removed by bedside debridement prior to assessing the percentage of clean, healthy, and viable wound bed.
5. has a negative urine or serum pregnancy test at screening (if female and has potential for pregnancy) and is willing to take precautionary measures to prevent pregnancy during the duration of the study (up to 9 days).

Exclusion Criteria

1. has been diagnosed with malignancy in the wound.
2. has untreated osteomyelitis.
3. has an untreated systemic infection.
4. has active cellulitis in the peri wound area.
5. has a known allergy or hypersensitivity to study materials: dressing and/or dressing components such as acrylic adhesives or polyurethane.
6. has, in the opinion of the investigator, a clinically significant condition that would impair the Subject's ability to comply with the study procedures.
7. has had radiation directly to the wound.
8. has been diagnosed with a major vascular deficit limiting arterial inflow to the wound region, as determined by the Investigator's interpretation of the Subject's medical history.
9. has eschar in the wound that cannot be removed by beside or sharp and/or mechanical debridement.
10. is participating in another interventional clinical trial for the duration of the study.
11. has unexplored fistulas in the wound or fistulas in the wound that connect to other body cavities.
12. has inadequate hemostasis at the wound site, as determined by the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
V.A.C. VERAFLO CLEANSE CHOICE™ with Normal Saline	V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline	-

Primary Outcome Measures

Name	Time	Method
Percent change in wound bed surface area (cm2) of clean, healthy, viable tissue	Baseline to Day 6-9

Secondary Outcome Measures

Name	Time	Method
Percent change in total wound area (cm2)	Baseline to Day 6-9
Percent change in total wound volume (cm3)	Baseline to Day 6-9
Physician assessment of the need for surgical debridement	Day 6-9	This will be a subjective assessment made by the Investigator of Yes or No

Trial Locations

Locations (1)

Joseph M. Still Research Foundation; 🇺🇸 Augusta, Georgia, United States